Trastuzumab amanitin antibody drug conjugate(Heidelberg Pharma AG)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrastuzumab amanitin antibody drug conjugate(Heidelberg Pharma AG)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionRNA polymerase II inhibitors
TargetsRNA polymerase II
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHeidelberg Pharma AG
China Registration ClassN/A

Develop Information

Active CompaniesHeidelberg Pharma AG
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A